Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-FLOT-TNT: Durvalumab + FLOT for Resectable Gastroesophageal Adenocarcinoma
NCT07507968Phase 2Not yet recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jul 2026
- Primary completion
- Feb 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in Esophago-Gastric Adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Pathological Complete Response at 13 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT07507968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507968.